Monitoring long-term Efficacy of Fampridine in Gait-Impaired Patients with Multiple Sclerosis
Neurol 88:832-841, Filli, L.,et al, 2017
Sustained-Release Oral Fampridine in Multiple Sclerosis: A Randomised, Double-Blind, Controlled Trial
Lancet 373:732-738, Goodman,A.D.,et al, 2009
4-Aminopyridine Toxicity with Unintentional Overdose in Four Patients with Multiple Sclerosis
Neurol 71:1833-1834, Burton,J.M.,et al, 2008
Quantitative Assessment of Sustained-Release 4-Aminopyridine for Symptomatic Treatment of Multiple Sclerosis
Neurol 48:817-821, Schwid,S.R.,et al, 1997
4-Aminopyridine in the Treatment of Patients with Multiple Sclerosis:Long-term Efficacy and Safety
Arch Neurol 51:292-296, Polman,C.H.,et al, 1994
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
The Effect of 4-Aminopyridine on Clinical Signs in Multiple Sclerosis
Ann Neurol 32:123-130, vanDiemen,H.A.M.,et al, 1992
4-Aminopyridine in Multiple Sclerosis:Prolonged Administration
Neurol 41:1344-1348, Stefoski,D.,et al, 1991
Orally Administered 4-Aminopyridine Improves Clinical Signs in Multiple Sclerosis
Ann Neurol 27:186-192, Davis,F.A.,et al, 1990
4-Aminopyridine Improves Clinical Signs in Multiple Sclerosis
Ann Neurol 21:71-77, Stefoski,D.,et al, 1987
Treatment with Oral 4-aminopyridine in Disorders of Neuromuscular Transmission
Neurol 31:265-271, Murray,N.M.F.,et al, 1981
4-Aminopyridine-A New Drug Tested in the Treatment of Eaton-Lambert Syndrome
JNNP 40:1109, Lundh,H.,et al, 1977
Validation of an Artificial Intelligence-Powered Virtual Assistant for Emergency Triage in Neurology
Neurologist 30:155-163, Alessandro,L.,et al, 2025
Neurological Diagnosis, Artificial Intelligence Compared with Diagnostic Generator
Neurologist doi.10.1097/NR.0000000000000560, Finelli,P.F., 2024
Large Language Models and the Degredation of the Medical Record
NEJM 391:1561-1564, McCoy,L.G.,et al, 2024
How Patients Are Using AI
BMJ 387:q2393, Stokel-Walker,C., 2024
Transformation of Undergraduate Medical Education in 2023
JAMA 330:1521-1522, Chang,B.S., 2023
Accuracy of a Generative Artificial Intelligence Model in a Complex Diagnostic Challenge
JAMA 330:78-79, Kanjee,Z.,et al, 2023
Improving Neurology Clinical Care with Natural Language Processing Tools
Neurol 101:1010-1018, Ge,W.,et al, 2023
Large Language Models in Neurology Research and Future Practice
Neurol 101:1058-1067, Romano,M.F.,et al, 2023
Will Generative Artificial Intelligence Deliver on Its Promise in Health Care?
JAMA doi.10.1001, Nov, Wachter R.M. & Brynjolfsson,E., 2023
Use of GPT-4 to Diagnose Complex Clinical Cases
NEJM AI doi:10.1056/AIp2300031, Eriksen,A.V.,et al, 2023
Study Finds ChatGPT Provides Inaccurate Responses to Drug Questions-Press Release
Am Soc Health Sys Pharm, Dec 5, Grossman,S., 2023
Artificial Intelligence and Machine Learning in Clinical Medicine, 2023
NEjM 388:1201-1208,1220, Haug,C.H. & Drazen,J.M., 2023
Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine
NEJM 388:1233-1239, Lee,P., et al, 2023
A New Case of Neuromyelitis Optica Spectrum Disorders with Unknown Fever and Subacute Cognitive Decline with Normal Images
Cureus 14:e24950, Furuya,K. & Itoh,M., 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Sequential Bilateral Vision Loss in a Woman with Scalp Tenderness and Jaw Claudication
JAMA Neurol 78:878-879, Kaufman, A.R.,et al, 2021
Aquaporin-4 and MOG Autoantibody Discovery in Idiopathic Transverse Myelitis Epidemiology
Neurol 93:e414-e420, Sechi, E.,et al, 2019
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
NEJM 381:614-625, Pittock, S.J.,et al, 2019
Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease
JAMA Neurol 75:65-71, Hamid, S.H.M.,et al, 2018
Area Postrema Syndrome
Neurol 91:e1642-e1651, Shosha, E.,et al, 2018
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
Neuromyelitis Optica Spectrum Disorders
UpToDate, May, Glisson,C.C., 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Persistent Hyperthermia in a Patient with Aquaporin-4-Antibody-Positive Neuromyelitis Optica Spectrum Disorder
J Clin Neurol 12:515-516, Hsu,C-L.,et al, 2016
Short Myelitis Lesions in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders
JAMA Neurol 72:81-87, Flanagan, E.P.,et al, 2015
International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders
Neurol 85:177-189, Wingerchuk, D.M.,et al, 2015
Opportunistic Infections of the Retina in Patients with Aquaporin-4 Antibody Disease
JAMA Neurol 71:1429-1432, George, J.S.,et al, 2014
Extensive Vasogenic Edema of Anti-Aquaporin-4 Antibody-Related Brain Lesions
Mult Scler 15:1113-1117, Matsushita, T.,et al, 2013
Brain Abnormalities as an Initial Manifestation of Neuromyelitis Optica Spectrum Disorder
MSJ 17:1107-1112, Kim, W.,et al, 2013
Differential Diagnosis of Neuromyelitis Optica Spectrum Disorders
Brain Neurol 62:953-960, Tanaka, T., 2013
Aquaporin-4 Antibody-Negative Neuromyelitis Optica
Neurol 80:2194-2200, 2176, Marignier, R.,et al, 2013
Longitudinally Extensive Transverse Myelitis with and Without Aquaporin 4 Antibodies
JAMA Neurol 70:1375-1381, Kitley, J.,et al, 2013
Aquaporin-4 Antibody-Negative Neuromyelitis Optica
Neurol 80:2194-2200,2176, Maringer, R.,et al, 2013
Aquaporin-4 Antibody-Positive Cases Beyond Current Diagnosis Criteria for NMO Spectrum Disorders
Neurol 80:2210-2216, Sato, D.,et al, 2013
Clinicopathologic Conference, Blind and Confused, Neuromyelitis Optica Spectrum Disorder
JAMA Neurol 70:932-936, Sharma, V.,et al, 2013
Anti-Aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with Balos Concentric Lesions
Intern Med 52:1517-1521, Masuda, H.,et al, 2013
Current Concept of Neuromyelitis Optica (NMO) and NMO Spectrum Disorders
JNNP doi:10.1136/JNNP-2012-302310, Jacob, A.,et al, 2012